Tags: Recurring

NCT02598349 – PAN009-18 A Phase II Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma

NCT00969111 – GU010-18 Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy

NCT01255748 – REG001-09 Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy

NCT05812807 – Alliance A012103, OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

NCT06313502 – High dose ascorbic acid (HDAA) in patients with plasma cell disorders

NCT04803201 – A051902 A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas

NCT06911502 – A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06661720 – A032201: Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-risk renal cell carcinoma – STRIKE

NCT05061550 – A Phase II Open-label, Multicenter, Randomized Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

NCT04239573 – EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

1
2
3
Next